论文部分内容阅读
目的:探讨非小细胞肺癌(NSCLC)患者肿瘤相关性贫血的特点。方法:统计122例NSCL行4个周期和6个周期化疗患者化疗前、化疗期间、复查期间血红蛋白(Hb)值,以及口服多糖铁复合物胶囊、叶酸、维生素B12三联药物治疗前后Hb值。结果:在行4个周期化疗的患者中,化疗1个周期与2个周期者Hb值差异有统计学意义(P<0.05)。化疗4个周期与6个周期的患者之间化疗前与末次化疗后Hb的差值(ΔHb)比较,差异无统计学意义(P>0.05)。13例患者在末次化疗后Hb值高于化疗前。在化疗全部结束后的3次复查中,患者Hb值差异无统计学意义(P>0.05)。化疗期间口服三联药物抗贫血治疗者服药前后ΔHb值与未用药患者比较,差异有统计学意义(P<0.05);化疗结束后服药者ΔHb值与未用药者比较,差异无统计学意义(P>0.05)。结论:行4个周期与6个周期化疗的患者Hb值下降程度相同;化疗期间及化疗结束后Hb值处于偏低且基本稳定的状态;口服三联药物可以改善患者化疗期间的贫血状况。
Objective: To investigate the characteristics of tumor-associated anemia in patients with non-small cell lung cancer (NSCLC). Methods: The hemoglobin (Hb) values before and after chemotherapy, chemotherapy and 122 patients with NSCL in 4 cycles and 6 cycles of NSCL were measured. The Hb values of three groups were compared before and after treatment with oral polysaccharide compound capsule, folic acid and vitamin B12. Results: Among 4 cycles of chemotherapy, there was a significant difference in Hb between 1 cycle and 2 cycles (P <0.05). There were no significant differences in Hb difference (ΔHb) between pre-chemotherapy and post-chemotherapy chemotherapy in 4 cycles of chemotherapy and 6 cycles of chemotherapy (P> 0.05). Thirteen patients had higher Hb after the last chemotherapy than before chemotherapy. There was no significant difference in Hb between 3 times after the chemotherapy was finished (P> 0.05). There were significant differences in ΔHb values between before and after taking oral triple anti-anemia medication before and after taking chemotherapy (P <0.05). There was no significant difference in ΔHb between before and after taking chemotherapy > 0.05). CONCLUSION: The Hb values of patients who underwent chemotherapy for 4 cycles and 6 cycles decreased in the same degree. Hb values were low and basically stable after chemotherapy and after chemotherapy. Oral triple therapy could improve anemia during chemotherapy.